EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hypoxia‐induced PGK1 expression promotes esophageal squamous cell carcinoma progression via stimulating MYH9‐mediated GSK3β/β‐catenin signalling

Jia-Cheng Xu, Lin-Feng Wu, Tian-Yin Chen, Yan-Bo Liu, Yi-Fei Zhang, Ping-Hong Zhou iD, Yi-Qun Zhang iD

Clinical and Translational Medicine · 2025

DOI: 10.1002/ctm2.70376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Jia-Cheng Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Phosphoglycerate Kinase, Esophageal Squamous Cell Carcinoma, beta Catenin, Glycogen Synthase Kinase 3 beta. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Engineering and Research Center of Diagnostic and Therapeutic Endoscopy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phosphoglycerate kinase 1 (PGK1) serves as a critical metabolic enzyme in the process of glycolysis and has many nonmetabolic functions in tumour progression. One of the most prevalent malignant tumours is still esophageal squamous cell carcinoma (ESCC), with high recurrence rates, high probabilities of metastasis, and poor prognoses. However, the molecular mechanisms and physiological contribution of PGK1 to ESCC carcinogenesis remain largely elusive.

Methods

Esophageal cancer bioinformatics analysis and tissue microarray analysis were employed to elucidate the aberrant expression of PGK1 during ESCC progression. The carcinogenic effect of PGK1 was examined using cell proliferation, migration and sphere formation assays. Mass spectrometry analysis, immunoprecipitation, ChIP and luciferase assays, hypoxia assays and in vitro and in vivo experiments were used to clarify the mechanism of the PGK1‒MYH9 interaction in the β‐catenin/c‐Myc signalling pathway.

Results

We clarified that in patients with ESCC, elevated PGK1 levels were linked to poor survival, tumour size, lymph node metastatic status, and TNM stage. In vivo and in vitro experimental analyses revealed that PGK1 promoted ESCC cell tumour stemness and EMT both in vivo and in vitro. Mechanistically, we discovered that PGK1 interacts with myosin‐9 (MYH9), leading to MYH9‐mediated ubiquitination‐mediated degradation of GSK‐3β, thereby triggering the β‐catenin signalling pathway and transcriptionally increasing c‐Myc expression. In addition, we found that hypoxic conditions upregulated PGK1, with HIF‐1α transactivating PGK1 expression, further promoting the PGK1‐MYH9 interaction and PGK1/MYH9/β‐catenin/c‐Myc axis activation.

Conclusions

PGK1 promotes ESCC tumourigenicity and migratory capacity by facilitating β‐catenin‐dependent c‐Myc transcription. Under hypoxic conditions, the PGK1‒MYH9 interaction is strengthened, and HIF‐1α‐mediated transcription increases PGK1 expression, thereby activating the β‐catenin/c‐Myc signalling pathway. Taken together, PGK1 holds promise as a potential biomarker for predicting postoperative prognosis and recurrence in patients with ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphoglycerate KinaseEsophageal Squamous Cell Carcinomabeta CateninGlycogen Synthase Kinase 3 betaEsophageal NeoplasmsMyosin Heavy ChainsHumansSignal TransductionMaleMiceAnimalsDisease ProgressionFemaleCell Line, Tumor

Stichwörter der Autor:innen

MYH9PGK1esophageal squamous cell carcinomahypoxiaβ‐catenin signalling pathway

Substanzen

Phosphoglycerate KinasePGK1 protein, humanbeta CateninGlycogen Synthase Kinase 3 betaMYH9 protein, humanMyosin Heavy ChainsGSK3B protein, humanCTNNB1 protein, human

Autor:innen und Institutionen

  • Department of Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Endoscopy, Shanghai Collaborative Innovation Center, Shanghai, China.

ORCID-Profile: Ping-Hong Zhou, Yi-Qun Zhang

Förderung

  • National Natural Science Foundation of China
  • Shanghai Engineering and Research Center of Diagnostic and Therapeutic Endoscopy

Zitieren

APA

Xu, J. C., Wu, L. F., Chen, T. Y., Liu, Y. B., Zhang, Y. F., Zhou, P. H., & Zhang, Y. Q. (2025). Hypoxia‐induced PGK1 expression promotes esophageal squamous cell carcinoma progression via stimulating MYH9‐mediated GSK3β/β‐catenin signalling. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70376

Vancouver

Xu JC, Wu LF, Chen TY, Liu YB, Zhang YF, Zhou PH, et al. Hypoxia‐induced PGK1 expression promotes esophageal squamous cell carcinoma progression via stimulating MYH9‐mediated GSK3β/β‐catenin signalling. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70376

BibTeX
@article{Xu2025,
  author = {Xu, Jia-Cheng and Wu, Lin-Feng and Chen, Tian-Yin and Liu, Yan-Bo and Zhang, Yi-Fei and Zhou, Ping-Hong and Zhang, Yi-Qun},
  title = {Hypoxia‐induced PGK1 expression promotes esophageal squamous cell carcinoma progression via stimulating MYH9‐mediated GSK3β/β‐catenin signalling},
  journal = {Clinical and Translational Medicine},
  year = {2025},
  doi = {10.1002/ctm2.70376}
}
Kostenlos starten →